Update on prostate cancer vaccines

Charles G. Drake

Research output: Contribution to journalArticle

Abstract

The recent approval of Sipuleucel-T (Dendreon, Seattle, WA) from the Food and Drug Administration for the treatment of men with asymptomatic or minimally symptomatic castrate-resistant prostate cancer was a landmark in cancer immunotherapy, making this the first cancer "vaccine" approved for use in a treatment setting. This approval has led to renewed interest in cancer vaccines and to the recognition that prostate cancer represents an immunologically sensitive disease. At the current time, several vaccine approaches are under clinical investigation. These include viral vectors, antigen-loaded dendritic cells, and DNA vaccines. Each approach has its own set of advantages and disadvantages. This review will introduce the basic technology underlying these different vaccines and briefly discuss completed and ongoing clinical trials. As a great number of prostate cancer vaccines have been investigated in both preclinical and clinical settings, we will focus primarily on vaccines that are currently in clinical trials, as ascertained by a recent inquiry of the clinical trials database, www.clinicaltrials.gov.

Original languageEnglish (US)
Pages (from-to)294-299
Number of pages6
JournalCancer Journal
Volume17
Issue number5
DOIs
StatePublished - Sep 2011

Fingerprint

Cancer Vaccines
Prostatic Neoplasms
Vaccines
Clinical Trials
DNA Vaccines
Viral Antigens
United States Food and Drug Administration
Immunotherapy
Dendritic Cells
Databases
Technology
Therapeutics
Neoplasms

Keywords

  • dendritic cell
  • GM-CSF
  • lymphocyte
  • Prostate
  • vaccine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Update on prostate cancer vaccines. / Drake, Charles G.

In: Cancer Journal, Vol. 17, No. 5, 09.2011, p. 294-299.

Research output: Contribution to journalArticle

Drake, Charles G. / Update on prostate cancer vaccines. In: Cancer Journal. 2011 ; Vol. 17, No. 5. pp. 294-299.
@article{2b00f47328864742ad5bd4cf5cfb0c5a,
title = "Update on prostate cancer vaccines",
abstract = "The recent approval of Sipuleucel-T (Dendreon, Seattle, WA) from the Food and Drug Administration for the treatment of men with asymptomatic or minimally symptomatic castrate-resistant prostate cancer was a landmark in cancer immunotherapy, making this the first cancer {"}vaccine{"} approved for use in a treatment setting. This approval has led to renewed interest in cancer vaccines and to the recognition that prostate cancer represents an immunologically sensitive disease. At the current time, several vaccine approaches are under clinical investigation. These include viral vectors, antigen-loaded dendritic cells, and DNA vaccines. Each approach has its own set of advantages and disadvantages. This review will introduce the basic technology underlying these different vaccines and briefly discuss completed and ongoing clinical trials. As a great number of prostate cancer vaccines have been investigated in both preclinical and clinical settings, we will focus primarily on vaccines that are currently in clinical trials, as ascertained by a recent inquiry of the clinical trials database, www.clinicaltrials.gov.",
keywords = "dendritic cell, GM-CSF, lymphocyte, Prostate, vaccine",
author = "Drake, {Charles G.}",
year = "2011",
month = "9",
doi = "10.1097/PPO.0b013e3182325e78",
language = "English (US)",
volume = "17",
pages = "294--299",
journal = "Cancer journal (Sudbury, Mass.)",
issn = "0765-7846",
publisher = "Association Pour le Developpement de la Communication Cancerologique",
number = "5",

}

TY - JOUR

T1 - Update on prostate cancer vaccines

AU - Drake, Charles G.

PY - 2011/9

Y1 - 2011/9

N2 - The recent approval of Sipuleucel-T (Dendreon, Seattle, WA) from the Food and Drug Administration for the treatment of men with asymptomatic or minimally symptomatic castrate-resistant prostate cancer was a landmark in cancer immunotherapy, making this the first cancer "vaccine" approved for use in a treatment setting. This approval has led to renewed interest in cancer vaccines and to the recognition that prostate cancer represents an immunologically sensitive disease. At the current time, several vaccine approaches are under clinical investigation. These include viral vectors, antigen-loaded dendritic cells, and DNA vaccines. Each approach has its own set of advantages and disadvantages. This review will introduce the basic technology underlying these different vaccines and briefly discuss completed and ongoing clinical trials. As a great number of prostate cancer vaccines have been investigated in both preclinical and clinical settings, we will focus primarily on vaccines that are currently in clinical trials, as ascertained by a recent inquiry of the clinical trials database, www.clinicaltrials.gov.

AB - The recent approval of Sipuleucel-T (Dendreon, Seattle, WA) from the Food and Drug Administration for the treatment of men with asymptomatic or minimally symptomatic castrate-resistant prostate cancer was a landmark in cancer immunotherapy, making this the first cancer "vaccine" approved for use in a treatment setting. This approval has led to renewed interest in cancer vaccines and to the recognition that prostate cancer represents an immunologically sensitive disease. At the current time, several vaccine approaches are under clinical investigation. These include viral vectors, antigen-loaded dendritic cells, and DNA vaccines. Each approach has its own set of advantages and disadvantages. This review will introduce the basic technology underlying these different vaccines and briefly discuss completed and ongoing clinical trials. As a great number of prostate cancer vaccines have been investigated in both preclinical and clinical settings, we will focus primarily on vaccines that are currently in clinical trials, as ascertained by a recent inquiry of the clinical trials database, www.clinicaltrials.gov.

KW - dendritic cell

KW - GM-CSF

KW - lymphocyte

KW - Prostate

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=80053341125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053341125&partnerID=8YFLogxK

U2 - 10.1097/PPO.0b013e3182325e78

DO - 10.1097/PPO.0b013e3182325e78

M3 - Article

C2 - 21952278

AN - SCOPUS:80053341125

VL - 17

SP - 294

EP - 299

JO - Cancer journal (Sudbury, Mass.)

JF - Cancer journal (Sudbury, Mass.)

SN - 0765-7846

IS - 5

ER -